EchoMD Automated Ejection Fraction Software vs Lung AI

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

EchoMD Automated Ejection Fraction Software

by Bay Labs (now Caption Health)

Lung AI

by Exo

AI Verdict

Tool A is designed for automated, precise left ventricular ejection fraction calculation from existing echocardiograms, integrating with PACS for efficiency. Tool B offers a handheld ultrasound platform with on-device AI for real-time cardiac and lung scanning, providing indicators for conditions like heart failure and pleural effusion during image acquisition. While both leverage AI for cardiac imaging, Tool A focuses on a specific post-acquisition measurement, whereas Tool B provides a broader, real-time diagnostic aid at the point of care.

Choose EchoMD Automated Ejection Fraction Software if…

Choose EchoMD Automated Ejection Fraction Software if your institution already performs a high volume of echocardiograms and you aim to enhance the efficiency and standardization of left ventricular ejection fraction (EF) calculations. This tool is ideal for integrating with existing DICOM PACS systems to automate clip selection and EF measurement, thereby reducing variability and streamlining the interpretation workflow for cardiologists.

View EchoMD Automated Ejection Fraction Software →

Choose Lung AI if…

Choose Lung AI by Exo if you require a portable, real-time AI-powered ultrasound solution for immediate diagnostic insights at the point of care, particularly in emergency or critical care settings. This handheld device is best suited for clinicians needing quick assessments for conditions like pleural effusion, consolidation, or basic cardiac indicators directly at the patient's bedside, without reliance on external internet connectivity.

View Lung AI →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	EchoMD Automated Ejection Fraction Software	Lung AI
Pricing	Contact for pricing	Contact for pricing
Deployment	On-premise (via DICOM PACS integration)	On-device (integrated with Exo Iris handheld ultrasound device)
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	1 AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Lung AI

Tool B (Lung AI) offers a comprehensive approach to usability with its handheld device, guided image capture, real-time feedback (SweepAI), and integrated AI-powered education (Exo U), making point-of-care ultrasound more accessible and easier to perform for multiple applications. Tool A (EchoMD) also enhances usability by automating complex echocardiogram tasks and guiding image acquisition, simplifying a specialized procedure for a broader range of users.

Clinical Value

Lung AI

Tool B (Lung AI) provides real-time AI-powered detection for multiple acute lung conditions (pleural effusion, consolidation/atelectasis) and cardiac indicators, enabling rapid, critical decision-making at the point of care. Tool A (EchoMD) offers high clinical value by providing accurate, consistent, and automated left ventricular ejection fraction (EF) calculation, reducing variability in a critical cardiac measurement.

Pricing & Value

Tie

Both tools require direct contact for pricing, and no public pricing details or specific return on investment (ROI) studies are readily available for either product. Without this crucial information, it is impossible to determine which tool offers better pricing or overall value.

Enterprise Readiness

EchoMD Automated Ejection Fraction Software

Tool A (EchoMD) integrates seamlessly with existing DICOM PACS systems, which is a standard and well-established integration model for large healthcare enterprises, leveraging existing IT infrastructure. Tool B (Lung AI) requires the adoption and management of a new, dedicated handheld hardware platform, which can present different challenges for large-scale deployment and device management within an enterprise.

Innovation

Lung AI

Tool B (Lung AI) demonstrates broader innovation by combining a novel, high-performance handheld ultrasound device with on-device AI for real-time, multi-application diagnostics, guided imaging, and integrated education. While Tool A (EchoMD) offers significant innovation in automating a complex cardiac measurement and guiding image acquisition, Tool B's holistic approach to point-of-care ultrasound represents a more disruptive and comprehensive advancement.

Support & Docs

Lung AI

Tool B (Lung AI) explicitly lists 'Exo U (AI-powered POCUS education and training)' as a key feature, indicating a dedicated and structured approach to user education and support. Tool A (EchoMD)'s provided information does not detail specific support or documentation offerings, making Tool B's commitment more evident.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	EchoMD Automated Ejection Fraction Software	Lung AI
Product Name	EchoMD Automated Ejection Fraction Software	Lung AI
Company	Bay Labs (now Caption Health)	Exo
Tagline	AI-powered automated ejection fraction calculation for echocardiograms.	Handheld AI Ultrasound for Smarter Cardiac and Lung Scanning.
Primary AI Cardiac Function	Automated Left Ventricular Ejection Fraction (EF) calculation	Automated AI-based indicators for cardiac conditions (e.g., heart failure, hypertrophy)
Other Primary AI Function	Not specified	AI-powered detection of pleural effusion, AI-powered detection of consolidation/atelectasis
Image Acquisition/Quality Feature	Automated clip selection for echocardiograms, Image quality rating and selection of best clips	Real-time feedback and image quality monitoring (SweepAI), Guided image capture for optimal scans

Videos

Demos, reviews, and walkthroughs featuring EchoMD Automated Ejection Fraction Software and Lung AI.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into a physician's existing clinical workflow for cardiac and lung evaluations?

EchoMD seamlessly integrates with existing DICOM PACS systems to automatically select optimal echocardiogram clips and calculate left ventricular ejection fraction, fitting into a cardiology lab's established workflow. Lung AI, integrated with the handheld Exo Iris device, offers real-time AI-powered detection and guided image capture for point-of-care cardiac and lung scanning, enabling immediate decisions at the bedside.

Beyond PACS integration for EchoMD, how do the results from both tools integrate with electronic health records (EHRs)?

EchoMD's seamless integration with DICOM PACS systems allows for the storage and potential transfer of automated EF calculations, which can then be integrated into EHRs via existing PACS workflows. For Lung AI, the on-device AI processing provides real-time insights, but the description does not specify direct EHR integration beyond the device itself, suggesting potential manual documentation or future export capabilities.

What specific claims exist regarding the accuracy and reliability of the AI-driven measurements or detections from each tool?

EchoMD claims to improve efficiency and accuracy in cardiac evaluation by reducing variability in EF measurement compared to manual methods, with observed variability superior at 8.29% compared to 9.2% for manual methods. Lung AI offers AI-powered detection of pleural effusion, consolidation/atelectasis, and automated AI-based indicators for cardiac conditions like heart failure and hypertrophy, implying diagnostic reliability for these specific findings.

For a physician managing both cardiac and pulmonary conditions, which tool offers a broader clinical utility or more immediate diagnostic support?

Lung AI provides broader utility for physicians managing both cardiac and pulmonary conditions, offering AI-powered detection for lung pathologies like pleural effusion and consolidation, alongside cardiac indicators, all in a handheld, real-time POCUS format. EchoMD is more specialized, focusing exclusively on automated ejection fraction calculation from echocardiograms, primarily benefiting cardiac evaluation workflows.

What is the expected learning curve for physicians to effectively incorporate each tool into their practice, and what training resources are available?

EchoMD integrates into existing PACS, suggesting the learning curve primarily involves familiarization with the automated EF output within current interpretation workflows. Lung AI emphasizes ease of use with 'guided image capture' and offers 'Exo U,' an AI-powered POCUS education and training platform, indicating a structured approach to help users quickly master the handheld device and its AI features.

How do these tools support documentation and auditability of AI-generated findings for clinical and administrative purposes?

EchoMD's seamless integration with DICOM PACS systems implies that its automated EF calculations are part of the standard imaging record, supporting existing documentation and audit trails within the PACS environment. While Lung AI performs on-device AI processing, the description does not explicitly detail specific audit-trail features for its real-time findings, suggesting the need for further inquiry into how these insights are logged and made auditable.

What are the key considerations for deploying and managing these AI tools across multiple clinical sites or departments?

For EchoMD, multi-site deployment would involve integrating the on-premise software with each site's existing DICOM PACS systems, requiring coordination with local IT infrastructure. Lung AI's on-device deployment model means managing the distribution, maintenance, and training for multiple Exo Iris handheld ultrasound devices across different sites or departments.